Martine Douha

576 total citations
13 papers, 455 citations indexed

About

Martine Douha is a scholar working on Epidemiology, Infectious Diseases and Virology. According to data from OpenAlex, Martine Douha has authored 13 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Epidemiology, 4 papers in Infectious Diseases and 3 papers in Virology. Recurrent topics in Martine Douha's work include Herpesvirus Infections and Treatments (12 papers), Virology and Viral Diseases (8 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). Martine Douha is often cited by papers focused on Herpesvirus Infections and Treatments (12 papers), Virology and Viral Diseases (8 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). Martine Douha collaborates with scholars based in Belgium, United States and Italy. Martine Douha's co-authors include Paul Willems, Thomas C. Heineman, Himal Lal, Susanna Esposito, Laura Cámpora, Lidia Oostvogels, Volker Schuster, Fred Zepp, Olivier Godeaux and K. von der Helm and has published in prestigious journals such as The Lancet, The Journal of Infectious Diseases and Vaccine.

In The Last Decade

Martine Douha

13 papers receiving 433 citations

Peers

Martine Douha
Luodan Suo China
Ruth Harbecke United States
Dana Perella United States
BRENDA O. STAEHLE United States
Zsófia Mészner Hungary
Anne Fiquet France
Maite Arriazu Spain
F.P.L. van Loon United States
Boonyarat Warachit Thailand
Naohide Takayama Japan
Luodan Suo China
Martine Douha
Citations per year, relative to Martine Douha Martine Douha (= 1×) peers Luodan Suo

Countries citing papers authored by Martine Douha

Since Specialization
Citations

This map shows the geographic impact of Martine Douha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martine Douha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martine Douha more than expected).

Fields of papers citing papers by Martine Douha

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martine Douha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martine Douha. The network helps show where Martine Douha may publish in the future.

Co-authorship network of co-authors of Martine Douha

This figure shows the co-authorship network connecting the top 25 collaborators of Martine Douha. A scholar is included among the top collaborators of Martine Douha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martine Douha. Martine Douha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Cámpora, Laura, Martine Douha, Thomas C. Heineman, et al.. (2017). Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine. The Journal of Infectious Diseases. 216(11). 1343–1351. 52 indexed citations
2.
Schwarz, Tino F., Naresh Aggarwal, Isabelle Schenkenberger, et al.. (2017). Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older. The Journal of Infectious Diseases. 216(11). 1352–1361. 59 indexed citations
3.
Cámpora, Laura, Martine Douha, Thomas C. Heineman, et al.. (2017). Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: A Phase III, Group-Matched, Clinical Trial. Open Forum Infectious Diseases. 4(suppl_1). S414–S414. 4 indexed citations
4.
Godeaux, Olivier, Martina Kovac, Daniel Shu, et al.. (2017). Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial. Human Vaccines & Immunotherapeutics. 13(5). 1051–1058. 45 indexed citations
5.
Vink, Peter, Masanari Shiramoto, Masayuki Ogawa, et al.. (2016). Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly. Human Vaccines & Immunotherapeutics. 13(3). 574–578. 23 indexed citations
6.
7.
Blatter, Mark M., Nicola P. Klein, Martin Schear, et al.. (2012). Immunogenicity and Safety of Two Tetravalent (Measles, Mumps, Rubella, Varicella) Vaccines Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children Twelve to Fourteen Months of Age. The Pediatric Infectious Disease Journal. 31(8). e133–e140. 20 indexed citations
8.
Knuf, Markus, Fred Zepp, K. von der Helm, et al.. (2011). Antibody persistence for 3 years following two doses of tetravalent measles–mumps–rubella–varicella vaccine in healthy children. European Journal of Pediatrics. 171(3). 463–470. 16 indexed citations
9.
Rümke, H. C., Karel Hoppenbrouwers, Corinne Vandermeulen, et al.. (2011). Immunogenicity and safety of a measles–mumps–rubella–varicella vaccine following a 4-week or a 12-month interval between two doses. Vaccine. 29(22). 3842–3849. 28 indexed citations
10.
Halperin, Scott A., David W. Scheifele, Gerald Predy, et al.. (2009). Safety and immunogenicity of a measles–mumps–rubella–varicella vaccine given as a second dose in children up to six years of age. Vaccine. 27(20). 2701–2706. 21 indexed citations
11.
Czajka, Hanna, Volker Schuster, Fred Zepp, et al.. (2009). A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra™): Immunogenicity and safety profile. Vaccine. 27(47). 6504–6511. 47 indexed citations
12.
13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luodan Suo Breakdown of academic impact, for papers by Ruth Harbecke Breakdown of academic impact, for papers by Dana Perella Breakdown of academic impact, for papers by BRENDA O. STAEHLE Breakdown of academic impact, for papers by Zsófia Mészner Breakdown of academic impact, for papers by Anne Fiquet Breakdown of academic impact, for papers by Maite Arriazu Breakdown of academic impact, for papers by F.P.L. van Loon Breakdown of academic impact, for papers by Boonyarat Warachit Breakdown of academic impact, for papers by Naohide Takayama
Rankless by CCL
2026